XTNT Stock Forecast 2025-2026
Distance to XTNT Price Targets
XTNT Price Momentum
🤔 Considering Xtant Medical (XTNT)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest XTNT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, XTNT has a bullish consensus with a median price target of $1.75 (ranging from $1.50 to $2.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.48, the median forecast implies a 264.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ryan Zimmerman at BTIG, projecting a 316.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XTNT Analyst Ratings
XTNT Price Target Range
Latest XTNT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XTNT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 16, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $3.00 |
| Dec 5, 2023 | BTIG | Ryan Zimmerman | Buy | Initiates | $2.00 |
| Jul 11, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $1.20 |
| Apr 26, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $1.00 |
| May 17, 2019 | Maxim Group | Hold | Downgrade | $0.00 | |
| Dec 8, 2016 | Maxim Group | Buy | Initiates | $0.00 | |
| Nov 30, 2016 | Aegis Capital | Buy | Initiates | $0.00 |
Xtant Medical Holdings Inc. (XTNT) Competitors
The following stocks are similar to Xtant Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xtant Medical Holdings Inc. (XTNT) Financial Data
Xtant Medical Holdings Inc. has a market capitalization of $66.75M with a P/E ratio of 75.1x. The company generates $117.27M in trailing twelve-month revenue with a -14.0% profit margin.
Revenue growth is +12.1% quarter-over-quarter, while maintaining an operating margin of -6.0% and return on equity of -34.9%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Xtant Medical Holdings Inc. (XTNT) Business Model
About Xtant Medical Holdings Inc.
Develops and distributes regenerative medicine products.
The company generates revenue through the sale of its innovative medical devices, specifically regenerative medicine products and surgical implants, targeting the orthopedic and neurological surgery markets. By providing essential tools to hospitals, surgical centers, and clinics, Xtant Medical enhances patient outcomes and supports complex injury treatments.
Xtant Medical Holdings aims to advance medical treatments by offering biologics and advanced materials that facilitate tissue healing and repair, establishing itself as a vital player in the medical technology sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
217
CEO
Mr. Sean E. Browne
Country
United States
IPO Year
2015
Website
www.xtantmedical.comXtant Medical Holdings Inc. (XTNT) Latest News & Analysis
Xtant Medical Holdings, Inc. will hold its Q4 2024 earnings conference call on March 6, 2025, at 4:30 PM ET. Participants include CEO Sean Browne and CFO Scott Neils.
Xtant Medical's Q4 results call signals upcoming financial performance insights, impacting investor sentiment and stock valuation based on growth and profitability trends.
Xtant Medical Holdings reported 2024 revenue of $117.3 million, up 28%. 2025 revenue is projected between $126M and $130M. Fourth-quarter revenue was $31.5 million, up 12%.
Xtant Medical's projected 28% revenue growth for 2024 and guidance of $126-$130 million for 2025, without needing extra capital, signals financial stability and potential for profitability, appealing to investors.
Xtant Medical to Issue Fourth Quarter and Year End 2024 Financial Results on March 6, 2025
16 days agoXtant Medical Holdings, Inc. will release its Q4 and full-year 2024 financial results on March 6, 2025, after market close, followed by a conference call at 4:30 PM ET.
Xtant Medical's upcoming financial results announcement and conference call could impact its stock price, reflecting investor sentiment on the company's performance and growth prospects.
Xtant Medical Holdings, Inc. will hold its Q3 2024 earnings conference call on November 12, 2024, at 4:30 PM ET, featuring CEO Sean Browne and CFO Scott Neils.
Xtant Medical's Q3 2024 earnings call may reveal financial performance and strategic insights, influencing stock valuation and investor sentiment.
Xtant Medical Holdings reported Q3 2024 revenue of $27.9 million, up 12% YoY, and reaffirmed full-year revenue guidance of $116-$120 million. They launched two new products and reported a net loss of $5 million.
Xtant Medical's 12% revenue growth and reaffirmed 2024 guidance signal strong demand and market expansion. New product launches may enhance future profitability, despite current net losses.
Xtant Medical Holdings, Inc. will attend the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, in New York, with CEO Sean Browne and CFO Scott Neils participating in 1x1 meetings.
Attendance at the Craig-Hallum Alpha Select Conference signals Xtant Medical's commitment to investor engagement, potentially influencing its stock performance and investor confidence in its growth prospects.
Frequently Asked Questions About XTNT Stock
What is Xtant Medical Holdings Inc.'s (XTNT) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Xtant Medical Holdings Inc. (XTNT) has a median price target of $1.75. The highest price target is $2.00 and the lowest is $1.50.
Is XTNT stock a good investment in 2025?
According to current analyst ratings, XTNT has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XTNT stock?
Wall Street analysts predict XTNT stock could reach $1.75 in the next 12 months. This represents a 264.6% increase from the current price of $0.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xtant Medical Holdings Inc.'s business model?
The company generates revenue through the sale of its innovative medical devices, specifically regenerative medicine products and surgical implants, targeting the orthopedic and neurological surgery markets. By providing essential tools to hospitals, surgical centers, and clinics, Xtant Medical enhances patient outcomes and supports complex injury treatments.
What is the highest forecasted price for XTNT Xtant Medical Holdings Inc.?
The highest price target for XTNT is $2.00 from Ryan Zimmerman at BTIG, which represents a 316.7% increase from the current price of $0.48.
What is the lowest forecasted price for XTNT Xtant Medical Holdings Inc.?
The lowest price target for XTNT is $1.50 from at , which represents a 212.5% increase from the current price of $0.48.
What is the overall XTNT consensus from analysts for Xtant Medical Holdings Inc.?
The overall analyst consensus for XTNT is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $1.75.
How accurate are XTNT stock price projections?
Stock price projections, including those for Xtant Medical Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
